Joshua J Meeks, MD, PhD

de Wit R et al. Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase 2 KEYNOTE-057 trial. ESMO 2018;Abstract 3575.

Giannarini G et al. Urologists, you’ll never walk alone! How novel immunotherapy and modern imaging may change the management of non-muscle-invasive bladder cancer. Eur Urol Oncol 2022;5(3):268-72. Abstract

Necchi A et al. Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial. Genitourinary Cancers Symposium2023;Abstract LBA442.

Steinberg RL et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 2020;203(5):902-9. Abstract

J Alfred Witjes, MD, PhD

Hautmann RE et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012;61(5):1039-47. Abstract

Martini A et al. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Cancer 2019;125(18):3155-63. Abstract

Waingankar N et al. The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer. Urol Oncol 2019;572.e21-8. Abstract

Sia Daneshmand, MD

Charmie K et al. Final clinical results of pivotal trial IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). ASCO 2023;Abstract 4508.

Charmie K et al. IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer. NEJM Evid 2022;2(1). Abstract.

Daneshmand S et al. First results from SunRISe-1 in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer receiving TAR-200 in combination with cetrelimab, TAR-200 or cetrelimab alone. AUA 2023;Abstract 02-03.

Daneshmand S et al. Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non–muscle-invasive bladder cancer (IR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 3 interim analysis. Genitourinary Cancers Symposium 2023;Abstract 504.

Daneshmand S et al. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: A phase I trial. Urol Oncol 2022;40(7):344.e1-9. Abstract

Kamat AM et al. Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress. Genitourinary Cancers Symposium 2023;Abstract TPS582.

Psutka SP et al. SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy. Genitourinary Cancers Symposium 2023;Abstract TPS584.

Tyson MD et al. Safety, tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder cancer who refused or were unfit for curative-intent therapy: A phase 1 study. J Urol 2023:209(5):890-900. Abstract

Vilaseca A et al. Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-in-human study. Genitourinary Cancers Symposium 2023;Abstract TPS583.

Matthew Milowsky, MD

Milowsky M et al. Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study. Genitourinary Cancers Symposium 2023;Abstract 439.

Rosenberg JE et al. Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC). ESMO 2022;Abstract LBA73.

Sridhar SS et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy. Genitourinary Cancers Symposium 2023;Abstract 508.

Arlene Siefker-Radtke, MD

Loriot Y et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. New Engl J Med 2019;381:338-48. Abstract

Siefker-Radtke A et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: Long-term follow-up of a phase 2 study. Lancet Oncol 2022;23(2):248-58. Abstract

Sheng X et al. Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma. ASCO 2022;Abstract 4518.